Jacquelyn Coloe Dosal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacquelyn Coloe Dosal has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Candido F. Pezon
Data Management, Miami Veterans Affairs Health System, Miami, Florida, USA
1 shared publicationChristianna S. Williams
Department of Dermatology, University of North Carolina, Chapel Hill, NC
1 shared publicationDean S. Morrell
Department of Dermatology, University of North Carolina, Chapel Hill, NC
1 shared publicationGeorgette L. Rodriguez
Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA; Department of Dermatology, Miami Veterans Affairs Health System, Miami, Florida, USA
1 shared publicationHua Li
Department of Epidemiology and Public Health, University of Miami Miller School of Medicine, Miami, Florida, USA
1 shared publicationJa‐An Lin
Department of Biostatistics, University of North Carolina, Chapel Hill, NC
1 shared publication
Latest Publications
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , 308-309
Rosacea and cardiovascular disease: Is there an association?
- 1 August 2015
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 73 (2) , 308-309
Rosacea and cardiovascular disease: Is there an association?
- 1 August 2014
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 134 (8) , 2267-2269
Effect of Tetracyclines on the Development of Vascular Disease in Veterans with Acne or Rosacea: A Retrospective Cohort Study
- 1 August 2014
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 134 (8) , 2267-2269
Effect of Tetracyclines on the Development of Vascular Disease in Veterans with Acne or Rosacea: A Retrospective Cohort Study
- 16 August 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 31 (4) , 440-449
Cantharidin for the Treatment of Molluscum Contagiosum: A Prospective, Double‐Blinded, Placebo‐Controlled Trial
Abstract: Our aim was to study the effects and safety of cantharidin in the treatment of molluscum contagiosum (MC), we conducted a prospective, double‐blinded, placebo‐controlled, randomized clinical trial to evaluate the safety and efficacy of topical cantharidin for treatment of pediatric MC in an academic ambulatory care center. Twenty‐nine children aged 5–10 with a diagnosis of MC were enrolled to receive treatment with cantharidin or placebo. The main outcome measure was complete clearance of all molluscum lesions. In contrast to previous retrospective observational studies, the performance of cantharidin treatment over 2 months was not substantially better than the performance of placebo. The scope of follow‐up was limited to five visits over 2 months of treatment. A longer follow‐up period might have captured a greater effect of cantharidin. Over a 2 month period, the magnitude of the cantharidin treatment effects in the target population are, at best, not large. This study provided objective unbiased estimates of the magnitude of cantharidin treatment effects and provided important prospective safety data. Our subjects experienced minimal side effects when treated with cantharidin.
- 16 August 2012
- Published by Wiley in Pediatric Dermatology
- Vol. 31 (4) , 440-449
Cantharidin for the Treatment of Molluscum Contagiosum: A Prospective, Double‐Blinded, Placebo‐Controlled Trial
Abstract: Our aim was to study the effects and safety of cantharidin in the treatment of molluscum contagiosum (MC), we conducted a prospective, double‐blinded, placebo‐controlled, randomized clinical trial to evaluate the safety and efficacy of topical cantharidin for treatment of pediatric MC in an academic ambulatory care center. Twenty‐nine children aged 5–10 with a diagnosis of MC were enrolled to receive treatment with cantharidin or placebo. The main outcome measure was complete clearance of all molluscum lesions. In contrast to previous retrospective observational studies, the performance of cantharidin treatment over 2 months was not substantially better than the performance of placebo. The scope of follow‐up was limited to five visits over 2 months of treatment. A longer follow‐up period might have captured a greater effect of cantharidin. Over a 2 month period, the magnitude of the cantharidin treatment effects in the target population are, at best, not large. This study provided objective unbiased estimates of the magnitude of cantharidin treatment effects and provided important prospective safety data. Our subjects experienced minimal side effects when treated with cantharidin.